Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Oct;38(10):2276–2279. doi: 10.1128/aac.38.10.2276

Longitudinal study of susceptibilities of species of the Bacteroides fragilis group to five antimicrobial agents in three medical centers.

P Turgeon 1, V Turgeon 1, M Gourdeau 1, J Dubois 1, F Lamothe 1
PMCID: PMC284730  PMID: 7840557

Abstract

A total of 579 clinical isolates of the Bacteroides fragilis group collected from three Canadian hospitals were tested for susceptibility to five antimicrobial agents by using an agar dilution method. During the 4-year survey, isolates from intra-abdominal infections were collected from the following sites: abdominal abscesses (48%), peritoneal fluid (39%), blood (10%), and bile (3%). B. fragilis was the most prevalent species (35.4%), followed by B. thetaiotaomicron (19.2%), B. ovatus (15.9%), and B. vulgatus (11%). No metronidazole- or imipenem-resistant strains were found during the survey. Resistance profiles varied among the different species tested: 7.8, 2.9, and 7.3% of B. fragilis strains (n = 205) and 68.1, 17.2, and 9.4% of non-B. fragilis strains (n = 373) were resistant to cefotetan, cefoxitin, and clindamycin, respectively. B. fragilis and B. vulgatus demonstrated lower resistance rates than B. thetaiotaomicron, B. ovatus, B. distasonis, and B. caccae. During the study, rates of resistance to cefotetan and clindamycin fluctuated but rates of resistance to cefoxitin increased, particularly at one center. These data indicate a need to determine the susceptibility patterns of the B. fragilis group periodically at each hospital.

Full text

PDF
2276

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Appelbaum P. C., Spangler S. K., Jacobs M. R. Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents. Antimicrob Agents Chemother. 1991 Jun;35(6):1214–1218. doi: 10.1128/aac.35.6.1214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Appleman M. D., Heseltine P. N., Cherubin C. E. Epidemiology, antimicrobial susceptibility, pathogenicity, and significance of Bacteroides fragilis group organisms isolated at Los Angeles County-University of Southern California Medical Center. Rev Infect Dis. 1991 Jan-Feb;13(1):12–18. doi: 10.1093/clinids/13.1.12. [DOI] [PubMed] [Google Scholar]
  3. Bandoh K., Ueno K., Watanabe K., Kato N. Susceptibility patterns and resistance to imipenem in the Bacteroides fragilis group species in Japan: a 4-year study. Clin Infect Dis. 1993 Jun;16 (Suppl 4):S382–S386. doi: 10.1093/clinids/16.supplement_4.s382. [DOI] [PubMed] [Google Scholar]
  4. Bourgault A. M., Harding G. K., Smith J. A., Horsman G. B., Marrie T. J., Lamothe F. Survey of anaerobic susceptibility patterns in Canada. Antimicrob Agents Chemother. 1986 Nov;30(5):798–801. doi: 10.1128/aac.30.5.798. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bourgault A. M., Lamothe F., Hoban D. J., Dalton M. T., Kibsey P. C., Harding G., Smith J. A., Low D. E., Gilbert H. Survey of Bacteroides fragilis group susceptibility patterns in Canada. Antimicrob Agents Chemother. 1992 Feb;36(2):343–347. doi: 10.1128/aac.36.2.343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cornick N. A., Cuchural G. J., Jr, Snydman D. R., Jacobus N. V., Iannini P., Hill G., Cleary T., O'Keefe J. P., Pierson C., Finegold S. M. The antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1987. J Antimicrob Chemother. 1990 Jun;25(6):1011–1019. doi: 10.1093/jac/25.6.1011. [DOI] [PubMed] [Google Scholar]
  7. Cuchural G. J., Jr, Tally F. P. Bacteroides fragilis: current susceptibilities, mechanisms of drug resistance, and principles of antimicrobial therapy. Drug Intell Clin Pharm. 1986 Jul-Aug;20(7-8):567–573. doi: 10.1177/106002808602000712. [DOI] [PubMed] [Google Scholar]
  8. Cuchural G. J., Jr, Tally F. P., Jacobus N. V., Aldridge K., Cleary T., Finegold S. M., Hill G., Iannini P., O'Keefe J. P., Pierson C. Susceptibility of the Bacteroides fragilis group in the United States: analysis by site of isolation. Antimicrob Agents Chemother. 1988 May;32(5):717–722. doi: 10.1128/aac.32.5.717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cuchural G. J., Jr, Tally F. P., Jacobus N. V., Cleary T., Finegold S. M., Hill G., Iannini P., O'Keefe J. P., Pierson C. Comparative activities of newer beta-lactam agents against members of the Bacteroides fragilis group. Antimicrob Agents Chemother. 1990 Mar;34(3):479–480. doi: 10.1128/aac.34.3.479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. De Almeida A. E., De Uzeda M. Susceptibility to five antimicrobial agents of strains of the Bacteroides fragilis group isolated in Brazil. Antimicrob Agents Chemother. 1987 Apr;31(4):617–618. doi: 10.1128/aac.31.4.617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Goldstein E. J., Citron D. M. Annual incidence, epidemiology, and comparative in vitro susceptibilities to cefoxitin, cefotetan, cefmetazole, and ceftizoxime of recent community-acquired isolates of the Bacteroides fragilis group. J Clin Microbiol. 1988 Nov;26(11):2361–2366. doi: 10.1128/jcm.26.11.2361-2366.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Horn R., Lavallée J., Robson H. G. Susceptibilities of members of the Bacteroides fragilis group to 11 antimicrobial agents. Antimicrob Agents Chemother. 1992 Sep;36(9):2051–2053. doi: 10.1128/aac.36.9.2051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lee K., Jang I. H., Kim Y. J., Chong Y. In vitro susceptibilities of the Bacteroides fragilis group to 14 antimicrobial agents in Korea. Antimicrob Agents Chemother. 1992 Jan;36(1):195–197. doi: 10.1128/aac.36.1.195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. O'Keefe J. P., Venezio F. R., DiVincenzo C. A., Shatzer K. L. Activity of newer beta-lactam agents against clinical isolates of Bacteroides fragilis and other Bacteroides species. Antimicrob Agents Chemother. 1987 Dec;31(12):2002–2004. doi: 10.1128/aac.31.12.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Suata K., Watanabe K., Ueno K., Homma M. Antimicrobial susceptibility patterns and resistance transferability among Bacteroides fragilis group isolates from patients with appendicitis in Bali, Indonesia. Clin Infect Dis. 1993 Apr;16(4):561–566. doi: 10.1093/clind/16.4.561. [DOI] [PubMed] [Google Scholar]
  16. Tally F. P., Cuchural G. J., Jr, Jacobus N. V., Gorbach S. L., Aldridge K., Cleary T., Finegold S. M., Hill G., Iannini P., O'Keefe J. P. Nationwide study of the susceptibility of the Bacteroides fragilis group in the United States. Antimicrob Agents Chemother. 1985 Nov;28(5):675–677. doi: 10.1128/aac.28.5.675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Wexler H. M., Finegold S. M. Antimicrobial resistance in Bacteroides. J Antimicrob Chemother. 1987 Feb;19(2):143–146. doi: 10.1093/jac/19.2.143. [DOI] [PubMed] [Google Scholar]
  18. Wexler H. M., Lavin P. T., Molitoris E., Finegold S. M. Statistical analysis of the effects of trial, reader, and replicates on MIC determination for cefoxitin. Antimicrob Agents Chemother. 1990 Nov;34(11):2246–2249. doi: 10.1128/aac.34.11.2246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Wexler H. M., Lavin P. T., Molitoris E., Finegold S. M. Statistical analysis of the effects of trial, reader, and replicates on MIC determination for cefoxitin. Antimicrob Agents Chemother. 1990 Nov;34(11):2246–2249. doi: 10.1128/aac.34.11.2246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Wexler H. M., Molitoris E., Finegold S. M. Effect of beta-lactamase inhibitors on the activities of various beta-lactam agents against anaerobic bacteria. Antimicrob Agents Chemother. 1991 Jun;35(6):1219–1224. doi: 10.1128/aac.35.6.1219. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES